E C Vamvakas

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi Scientific background on the risk engendered by reducing the lifetime blood donation deferral period for men who have sex with men
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Transfus Med Rev 23:85-102. 2009
  2. ncbi Is human herpesvirus-8 transmitted by transfusion?
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Transfus Med Rev 24:1-14. 2010
  3. ncbi Rationale for randomized controlled trials and for intention-to-treat analysis in transfusion medicine: are they one and the same?
    E C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Vox Sang 95:165-73. 2008
  4. ncbi Universal white blood cell reduction in Europe: has transmission of variant Creutzfeldt-Jakob disease been prevented?
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, 8700 Beverly Blvd, Room 3733, Los Angeles, CA 90048, USA
    Transfus Med Rev 25:133-44. 2011
  5. ncbi Relative risk of reducing the lifetime blood donation deferral for men who have had sex with men versus currently tolerated transfusion risks
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Transfus Med Rev 25:47-60. 2011
  6. ncbi Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Transfusion 51:1058-71. 2011
  7. ncbi The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Clin Lab 56:263-79. 2010
  8. ncbi Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Transfus Med Rev 24:77-124. 2010
  9. ncbi Meta-analysis of clinical studies of the purported deleterious effects of "old" (versus "fresh") red blood cells: are we at equipoise?
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Transfusion 50:600-10. 2010
  10. ncbi Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Transfusion 49:2743-58. 2009

Collaborators

Detail Information

Publications12

  1. ncbi Scientific background on the risk engendered by reducing the lifetime blood donation deferral period for men who have sex with men
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Transfus Med Rev 23:85-102. 2009
    ....
  2. ncbi Is human herpesvirus-8 transmitted by transfusion?
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Transfus Med Rev 24:1-14. 2010
    ....
  3. ncbi Rationale for randomized controlled trials and for intention-to-treat analysis in transfusion medicine: are they one and the same?
    E C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Vox Sang 95:165-73. 2008
    ..Nonetheless, the rationale for ITT can be reversed in equivalence and non-inferiority trials where the finding of no difference is the objective of the research; thus, both ITT and AT analyses should be presented in these settings...
  4. ncbi Universal white blood cell reduction in Europe: has transmission of variant Creutzfeldt-Jakob disease been prevented?
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, 8700 Beverly Blvd, Room 3733, Los Angeles, CA 90048, USA
    Transfus Med Rev 25:133-44. 2011
    ..Accordingly, universal WBC reduction for the prevention of vCJD in Europe should continue...
  5. ncbi Relative risk of reducing the lifetime blood donation deferral for men who have had sex with men versus currently tolerated transfusion risks
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Transfus Med Rev 25:47-60. 2011
    ....
  6. ncbi Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Transfusion 51:1058-71. 2011
    ..Meta-analysis was used to calculate the effect of pathogen reduction (PR) of PLTs on hemostatic efficacy and capacity based on all available data and to investigate possible reasons for the variation in reported findings...
  7. ncbi The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Clin Lab 56:263-79. 2010
    ..The latter cannot protect from vCJD and potentially also from some other emerging TTIs; moreover, they have recently been associated with an increased risk of bleeding...
  8. ncbi Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Transfus Med Rev 24:77-124. 2010
    ....
  9. ncbi Meta-analysis of clinical studies of the purported deleterious effects of "old" (versus "fresh") red blood cells: are we at equipoise?
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Transfusion 50:600-10. 2010
    ..Such suspicion is required for intentionally exposing patients enrolled in randomized controlled trials (RCTs) to the known or probable--but rare--risks of old RBCs, to document (and prevent) purported common adverse effects of old RBCs...
  10. ncbi Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Transfusion 49:2743-58. 2009
    ....
  11. ncbi Risk-reduction strategies for platelet transfusion in the United States
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
    ScientificWorldJournal 11:624-40. 2011
    ....
  12. ncbi Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention
    Eleftherios C Vamvakas
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Blood 113:3406-17. 2009
    ....